drugset / Trial / NCT03836859

Study to Evaluate Safety, Tolerability & PK of rhNGF in Healthy Volunteers

NCT03836859 ↗

Phase 1 Completed 30 enrolled Dompé Farmaceutici S.p.A Cromsource · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of this study is to assess the safety and tolerability of a single short-term and a multiple dose scheme of rhNGF when administered as eye drops in healthy subjects of Japanese ethnicity. The secondary objective of this study is to assess the pharmacokinetics of single and multiple doses of rhNGF when administered as eye drops in healthy subjects of Japanese ethnicity.

Timeline

Start
2018-03-30
Primary completion
2018-06-01
Completion
2018-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject rhNGF Protein / enzyme biologic 20 ug/ml Other

Indications

No indication recorded.